Seven cases of Saccharomyces fungaemia related to use of probiotics

Autor:	Soma Dutta, Arunaloke Chakrabarti, Laxman G Jessani, Joseph Jillwin, Shivaprakash M Rudramurthy, Ujjwayini Roy, Ram Gopalakrishnan, Chandrashish Chakravarty
Rok vydání:	2017
Předmět:	Adult Male 0301 basic medicine Antifungal medicine.medical_specialty Antifungal Agents medicine.drug_class Critical Illness 030106 microbiology India Microbial Sensitivity Tests Saccharomyces cerevisiae Dermatology Saccharomyces law.invention Microbiology Echinocandins 03 medical and health sciences Probiotic 0302 clinical medicine Drug Resistance Fungal law Clinical history Internal medicine medicine Humans Amplified Fragment Length Polymorphism Analysis Medical prescription Aged Voriconazole biology business.industry Probiotics Broth microdilution Infant Newborn General Medicine biology.organism_classification Intensive care unit Saccharomyces boulardii Infectious Diseases RNA Ribosomal Multigene Family Female 030211 gastroenterology & hepatology business Fungemia medicine.drug
Zdroj:	Mycoses. 60:375-380
ISSN:	0933-7407
DOI:	10.1111/myc.12604
Popis:	Summary Probiotics are increasingly used in critically ill patients without enough safety data. The aim of the present study was to determine the association of probiotics with Saccharomyces cerevisiae fungaemia. Seven patients with S. cerevisiae fungaemia were reported at two hospitals in India between July 2014 and September 2015. Detailed clinical history of patients was recorded. Besides the seven patient isolates, three probiotics sachets used in those patients and five unrelated clinical isolates were used for association study by Fluorescent amplified fragment length polymorphism (FAFLP). Antifungal susceptibility testing was performed by broth microdilution technique of CLSI (M27-A3) and interpreted according to CLSI (M27S4). Two patients were premature neonates and five were adults. They were admitted in intensive care unit and were on probiotics containing S. boulardii (except one adult patient). FAFLP analysis showed 96.4-99.7% similarity between blood and corresponding probiotic isolates. Of the three AFLP types (group I, II, II) identified, all the probiotic isolates clustered in group I (major cluster) including majority of the blood isolates. The isolates were susceptible to all antifungal agents tested. Five patients, who could be evaluated, responded promptly to echinocandins or voriconazole. As the prescription of probiotic containing S. boulardii in critically ill patient's leads to the fungaemia, we recommend avoiding this probiotic in those patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d920bf7feac2dd937c5a39d2d4f171 https://doi.org/10.1111/myc.12604 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.